Advertisement
Browse Subject Areas
?

Click through the PLOS taxonomy to find articles in your field.

For more information about PLOS Subject Areas, click here.

  • Loading metrics

Open Access

Correction

Correction: Preclinical Assessment of Carboplatin Treatment Efficacy in Lung Cancer by 18F-ICMT-11-Positron Emission Tomography

  • Timothy H. Witney,
  • Robin Fortt,
  • Eric O. Aboagye

Following the publication and correction of this article [1, 2], an error in Fig 3B(ii) has been identified whereby the wrong panel for ‘Total PARP’ was used inadvertently. The updated figure presents the correct ‘Total PARP’ panel for Fig 3B(ii), and the original, uncropped blots supporting the results in Fig 3B(ii) as well as the individual level data supporting Fig 3A, 3C and 3D have been uploaded as Supporting Information files.

thumbnail
Download:
Fig 3. Temporal changes in cell death markers and 18F-ICMT-11 uptake after carboplatin treatment.

A: Time course of changes in caspase 3/7 activity following carboplatin treatment. B: Western blot analysis of the levels of uncleaved PARP, cleaved PARP and cleaved (active) caspase 3 post 50 μM carboplatin treatment (0–96 h) in PC9 (i) and A549 cells (ii). C: Temporal changes in 18F-ICMT-11 uptake in cells following carboplatin treatment. D: Correlation between caspase 3 activity and 18F-ICMT-11 uptake in PC9 cells.

https://doi.org/10.1371/journal.pone.0235804.g001

Supporting information

S1 Fig. Original Actin, Cleaved Caspase 3, and PARP blots underlying Fig 3B(ii).

https://doi.org/10.1371/journal.pone.0235804.s001

(TIF)

S1 Table. Individual level data underlying Fig 3A: Time course of changes in caspase 3/7 activity following carboplatin treatment.

https://doi.org/10.1371/journal.pone.0235804.s002

(XLSX)

S2 Table. Individual level data underlying Fig 3C: Temporal changes in 18F-ICMT-11 uptake in cells following carboplatin treatment.

https://doi.org/10.1371/journal.pone.0235804.s003

(XLSX)

S3 Table. Individual level data underlying Fig 3D: Correlation between caspase 3 activity and 18F-ICMT-11 uptake in PC9 cells.

https://doi.org/10.1371/journal.pone.0235804.s004

(XLSX)

References

  1. 1. Witney TH, Fortt R, Aboagye EO (2014) Preclinical Assessment of Carboplatin Treatment Efficacy in Lung Cancer by 18F-ICMT-11-Positron Emission Tomography. PLoS ONE 9(3): e91694. https://doi.org/10.1371/journal.pone.0091694 pmid:24618809
  2. 2. The PLOS ONE Staff (2014) Correction: Preclinical Assessment of Carboplatin Treatment Efficacy in Lung Cancer by 18F-ICMT-11-Positron Emission Tomography. PLoS ONE 9(6): e100020. https://doi.org/10.1371/journal.pone.0100020

Citation: Witney TH, Fortt R, Aboagye EO (2020) Correction: Preclinical Assessment of Carboplatin Treatment Efficacy in Lung Cancer by 18F-ICMT-11-Positron Emission Tomography. PLoS ONE 15(7): e0235804. https://doi.org/10.1371/journal.pone.0235804

Published: July 9, 2020

Copyright: © 2020 Witney et al. This is an open access article distributed under the terms of the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited.